Our recent outcomes and needs assessment data demonstrate a dramatic negative “awareness shift” of key treatment information among both hematologists and oncologists. Practice-changing data are now emerging so quickly, and in such great volume, that treating oncologists do not learn about new agents and integrate the latest data until much later in the drug development process and, in many cases, not until well after agents have been approved for use. In this White Paper, we highlight the key findings, and suggest innovative changes to CME offerings that recognize this deficit and could help mitigate these gaps and improve patient care. Although this analysis is specific to our hematology/oncology data, we believe the same lessons apply in areas such as rheumatology/immunology, virology, and other therapeutic areas where the pace of change is increasing as well.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.